Melanoma
📧 Sign up to get email alerts when something new happens for Melanoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-01-14Clinical Trial Update: Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs. [Phase 2]
Phase 2 clinical trial evaluating Prifetrastat (PF-07248144) in combination with Fulvestrant for HR+/HER2- breast cancer. The study is plann…
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: A Clinical Study of T3011 in Subjects With Advanced Melanoma [Phase 1, Phase 2]
A clinical trial update for a Phase 1/2 study of T3011 in patients with melanoma, currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-01-12Clinical Trial Update: A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients
This document reports the completion of a prospective observational study evaluating targeted therapy for unresectable or metastatic BRAFV60…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma [Phase 3]
A Phase 3 study evaluating Amgen's ABP-206 versus Opdivo (nivolumab) in unresectable or metastatic melanoma. The trial is currently active b…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
A clinical trial update describes long-term safety outcomes in patients previously treated with RP1, RP2, or RP3 and is currently recruiting…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma [Phase 1, Phase 2]
This update covers the Phase 1/2 study of the investigational agent NUC-7738 in patients with advanced solid tumors and lymphoma, focusing o…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment [Phase 2]
This ClinicalTrials.gov entry describes a Phase 2 study to assess the long-term health of adults who previously participated in a melanoma t…
-
CLINICAL_TRIALS trial_result · 2026-01-09Clinical Trial Update: Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain [Phase 2]
A Phase 2 trial evaluating low-dose ipilimumab in combination with pembrolizumab for metastatic melanoma with brain metastases has completed…
-
CLINICAL_TRIALS trial_result · 2026-01-08Clinical Trial Update: A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma [Phase 3]
Phase 3 trial evaluating adjuvant nivolumab plus relatlimab vs nivolumab alone after complete resection of stage III-IV melanoma was termina…
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors [Phase 1]
A Phase 1 clinical trial from AgonOx is evaluating cancer-specific CD8+ TIL-based adoptive cell therapy in adults with solid tumors, includi…
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies
A clinical trial update examining how immune checkpoint inhibitors and other immunotherapies may drive tumor evolution through treatment-ind…
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma [Phase 2]
Phase 2 clinical trial evaluating a PD-1 antibody therapy in combination with infliximab for metastatic melanoma.
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: Integrated Molecular Profiling in Advanced Cancers Trial
An ongoing trial, Integrated Molecular Profiling in Advanced Cancers, sponsored by University Health Network in Toronto, investigates using …
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors [NA]
This entry reports a recruiting clinical trial evaluating urolithin A in patients with previously untreated solid tumors receiving immune ch…
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies
A clinical trial funded by Elephas is exploring a biomarker-based method to predict response to immunotherapy using live tumor biopsies; the…
-
CLINICAL_TRIALS other · 2026-01-08Clinical Trial Update: Compassionate Use of Vidutolimod
The compassionate-use program for Vidutolimod in patients with melanoma is no longer available.
-
CLINICAL_TRIALS trial_result · 2026-01-07Clinical Trial Update: Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
A completed pilot trial evaluating pro-inflammatory cytokine kinetics during immune checkpoint inhibitor therapy. It explores inflammatory r…
-
CLINICAL_TRIALS trial_result · 2026-01-07Clinical Trial Update: Measuring Real Time Decision-Making About Ultraviolet Radiation (UVR) Protection
The clinical trial evaluating real-time decision-making about ultraviolet radiation protection in melanoma has completed, with results poste…
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors [Phase 1]
A Phase 1 trial evaluating in situ immunomodulation using CDX-301, CDX-1140, and Poly-ICLC with radiation therapy in patients with unresecta…
-
EMA approval · 2026-01-06EMA Authorised: Imlygic (talimogene laherparepvec) — Amgen Europe B.V.
The EMA authorised Imlygic (talimogene laherparepvec) for melanoma, with Amgen Europe B.V. as the marketing authorisation holder; decision d…
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: Cryoablation+Ipilimumab+Nivolumab in Melanoma [Phase 2]
A Phase 2 clinical trial at Massachusetts General Hospital is evaluating the combination of cryoablation with ipilimumab and nivolumab for m…
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: CARE-Melanoma Trial [Phase 1]
Clinical trial update for CARE-Melanoma, a Phase 1 study in melanoma that is currently NOT_YET_RECRUITING.
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma [Phase 2]
A Phase 2 clinical trial is evaluating PET-guided stereotactic body radiation therapy for oligoprogressive disease in non-small cell lung ca…
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma [Phase 2]
A Phase 2 clinical trial is evaluating the combination of the IL-6 receptor inhibitor sarilumab with ipilimumab, nivolumab, and relatlimab f…
-
CLINICAL_TRIALS withdrawal · 2026-01-02Clinical Trial Update: NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis [Phase 1, Phase 2]
A phase 1/2 trial of NovoTTF-200A in combination with pembrolizumab for metastatic melanoma with brain metastases has been withdrawn.